The effect of MYO18B mRNA suppression was stronger in bFGF treated conditions (Fig. 3C), which stand in line with the negative correlation of FGF2 with MYO18B in HCC patients (Fig. 3A). The gene discussed is FGF2; the disease is hepatocellular carcinoma.